Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 25, 2017

DrugPatentWatch Database Preview

Selegiline - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for selegiline and what is the scope of selegiline patent protection?

Selegiline
is the generic ingredient in four branded drugs marketed by Somerset, Stason, Apotex, G And W Labs Inc, Chartwell Molecules, Lannett Holdings Inc, Dava Pharms Inc, Mylan, Apotex Inc, Siegfried, and Valeant Pharm Intl, and is included in sixteen NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selegiline has three patent family members in two countries.

There are sixteen drug master file entries for selegiline. One supplier is listed for this compound.

Summary for Generic Name: selegiline

Tradenames:4
Patents:4
Applicants:11
NDAs:16
Drug Master File Entries: see list16
Suppliers / Packagers: see list1
Bulk Api Vendors: see list15
Clinical Trials: see list9
Patent Applications: see list7,419
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:selegiline at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
G And W Labs Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074537-001Aug 2, 1996DISCNNoNo► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-002Feb 27, 2006RXYesNo7,150,881► SubscribeYY ► Subscribe
G And W Labs Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074744-001Jan 27, 1997DISCNNoNo► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-001Feb 27, 2006RXYesYes7,638,140► SubscribeY ► Subscribe
Lannett Holdings Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
CAPSULE;ORAL075145-001Sep 15, 2003DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot